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INJECTING DRUG USERS (IDUS) COMPRISE THE
LARGEST SHARE OF HIV CASES in at least 20 nations of
Asia and the former Soviet Union, including China and
Russia.1 Yet as these countries move to make HIV treatment
more available, IDUs remain disproportionately less likely
to have access to antiretroviral (ARV) treatment.2 Reasons
for this inequality include misconceptions about the impact
of drug use on treatment adherence, denial of basic supports
such as methadone that would facilitate HIV treatment, 
stigma in health care settings, and emphasis on incarceration
and punishment of IDUs rather than on their care.3,4,5,6,7,8
HIV Treatment Shortfalls:
Gaps in ARVs for IDUs 
Though nearly one in three HIV cases outside Africa is
attributed to injecting drug use, ARV treatment systems
continue to exclude IDUs.9
In Eastern Europe and Central Asia, IDUs represent more
than 80 percent of HIV cases, but only 14 percent of the
total number of people receiving ARVs.10
In Russia, where approximately 83 percent of total HIV
cases are IDUs,11 as many as 70,000 people are in need of
ARV treatment. Only 30,000 receive it. ARV stockouts 
are an ongoing problem in Russia.12
In Thailand, where more than 80% of people in need of
ARV treatment receive it, the country has failed to system-
atically extend treatment to drug users; some providers
openly deny drug users treatment.13
In China, Malaysia, and Vietnam, IDUs are interned for
months or years in forced detoxification and rehabilitation
centers. Though many IDUs are HIV-positive, few centers
offer ARVs.14,15,16
In Malaysia, IDUs comprise 75 percent of all HIV cases
but only 5 percent of those receiving ARV treatment.17
HIV Treatment Benefits: Clinical Efficacy 
of ARVs for IDUs 
Medical providers are often reluctant to treat IDUs, claiming
that their lives are too chaotic for them to adhere to anti-
retroviral treatment or that multiple illnesses make treatment
too difficult.18,19 While active drug use has been linked to
problems with access and adherence to ARV treatment,
IDUs offered appropriate supports can achieve adherence
and treatment outcomes comparable to those of other
patients.20,21
A 2006 study in France determined that a history of
injecting drug use had no significant effect on adherence
to ARV treatment.22
A 2004 study of patients in Vancouver (Canada) found
that drug users who adhered to ARV experienced the
same increases in CD4+ count as adherent non–drug
users.23
In a 2000 study in Sao Paolo (Brazil) active drug use 
had no impact on ARV adherence; 69 percent of patients
achieved adherence levels of over 80 percent, though
most were poor, had limited education, and were unem-
ployed.24
A 1999 study of patients receiving ARV treatment from
51 centers across Europe found no significant difference
between IDUs and non–drug users in CD4+ or virologic
response.25
HIV Treatment Tool: Opiate Substitution 
Therapy and ARVs for IDUs 
Prescribed medications such as methadone or buprenor-
phine are the best studied and most effective form of 
treatment for opiate dependence.26 Substitution therapy
allows patients to stop or reduce illicit drug use and injec-
tion, improve their health, stabilize their lives, and adhere
to ARV regimens.27 The World Health Organization added
methadone and buprenorphine to its list of essential 
medicines in 2005.
Despite its effectiveness, opiate substitution therapy
remains strikingly limited. Of 6 and a half million IDUs
estimated to live in countries where contaminated needles
are the main source of HIV infections, only 130,000 have
access to substitution therapy.28 In Russia, with more than
2 million IDUs, opiate substitution therapy is illegal.29
HIV Treatment Needs: Integrated,
Comprehensive Care for IDUs 
Drug use is often linked to other factors that may affect
HIV treatment, including poverty, psychiatric illness, 
and infection with hepatitis C or tuberculosis. Offering
multiple services at a single site and creating strong 
links between HIV, TB, and drug treatment providers can
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increase accessibility and effectiveness of ARVs for IDUs.
Keeping programs open late, situating them in areas con-
venient for drug users, and including peer outreach work-
ers and counselors in treatment provision also increases
the effectiveness of health care for IDUs.30,31,32,33 Directly
administered antiretroviral therapy (DAART), in which
program staff supervise delivery of ARV treatment, can
also increase adherence.34,35
A New York City program offered patients peer education
and counseling, support in disclosing HIV status to 
family members, and referrals to drug treatment and
housing services. The caregiving team included a social
worker and a nurse as well as a physician. New patients
received prefilled pillboxes and counseling every week. 
In a 2004 study of the program, nearly nine in ten (86
percent) achieved an undetectable viral load after one
year. Only one in three patients who did not receive such
support achieved the same result.36
A 2004 study of a program in New Haven (USA) found
that 77 percent of drug users who were offered peer 
support and DAART at a mobile health clinic achieved
an undetectable viral load. Adherence among these IDUs
was 85 percent despite the fact that 35 percent were
homeless and 74 percent were depressed.37
A 2005 study in Baltimore (USA) showed that IDUs who
received DAART in methadone clinics were significantly
more likely to adhere than patients who self-adminis-
tered their ARV, including IDUs on or off methadone
and non-IDUs.38
“Access to HIV treatment should not be artificially
restricted due to political or social constraints.
Specifically there should be no categorical exclusion
of injection drug users from any level of care.”39
World Health Organization, Protocols on HIV/AIDS Treatment 
and Care for the Commonwealth of Independent States, 2004
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